Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g., blood diorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 2777 polypeptide activity or aberrant 2777 nucleic acid expression.

Abstract: The present invention provides recombinant triple helical proteins or collagen-like proteins comprising a prokaryotic protein or one or more domains of a prokaryotic protein comprising a collagen-like peptide sequence of repeated Gly-Xaa-Yaa triplets and, optionally, one or more domains from a mammalian collagen. Also provided are expression vectors and host cells containing the expression vectors to produce these recombinant proteins and methods of production for the same. Additionally, antibodies are provided that are directed against a recombinant collagen-like protein that, preferably, binds an integrin. Furthermore, a method of screening for potential therapeutic compounds that inhibit the integrin-binding or -interacting activities of recombinant collagen-like proteins.

Abstract: A preparation is provided which can be injected or implanted into the human or animal body, and which comprises, as main component, globin that is insoluble at physiological pH, biocompatible and sterile.

Abstract: Novel Pichia methanolica secretory signal polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using are disclosed. Methods of producing large amounts of recombinant proteins by employing DNA constructs having a polypeptide of interest preceded by a novel Pichia methanolica secretory signal sequence.

Abstract: The invention relates to serine protease inhibitors having the amino acid sequence in accordance with Seq. ID No. 1.

Abstract: Described herein is the discovery that human interleukin-1? convertase (ICE) is structurally similar to the protein encoded by the C. elegans cell death gene, ced-3. Comparative and mutational analyses of the two proteins, together with previous observations, suggest that the Ced-3 protein may be a cysteine protease like ICE and that ICE may be a human equivalent of the nematode cell death gene. Another mammalian protein, the murine NEDD-2 protein, was also found to be similar to Ced-3. The NEDD-2 gene is implicated in the development of the murine central nervous system. On the basis of these findings, novel drugs for enhancing or inhibiting the activity of ICE, ced-3, or related genes are provided. Such drugs may be useful for treating inflammatory diseases and/or diseases characterized by cell deaths, as well as cancers, autoimmune disorders, infections, and hair growth and hair loss. Furthermore, such drugs may be useful for controlling pests, parasites and genetically engineered organisms.

Abstract: The present invention concerns a method for the separation and/or isolation of inhibitors of cellulolytic, xylanolytic and/or beta-glucanolytic enzymes, inhibitors obtainable by said method, and process for obtaining micro-organism, plant or plant material wherein the activity of the inhibitor according to the invention is increased or reduced and to the use of the inhibitor, using the cited micro-organism, plant or plant material and/or the use of endoxylanases selected or modified using these inhibitors in a variety of process and applications.

Abstract: The invention discloses a new kind of RNA binding protein 33 and polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. It also discloses the method of applying the polypeptide for the treatment of various kinds of diseases, such as cancer, hemopathology, HIV infection, immune diseases and inflammation. The antibody and antagonist of the polypeptide and the therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said RNA binding protein 33.

Abstract: The use of CCH-A subunit isolated from hemocyanin of the marine gastropod Concholepas concholepas (CCH), or a combination thereof, as an immunostimulant agent in the innate or adaptive immune response of vertebrates or as an immunotherapeutic agent in cancer of either humans or animals, where the CCH-A subunit has a molecular weight of about 404 kDa, is stable in the absence of Ca+2 and Mg+2 and is at least 95% pure.

Abstract: Scramblase 2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing scramblase 2 polypeptides and polynucleotides in diagnostic assays.

Abstract: The present invention provides a novel protein and its use. The protein or its salt, the partial protein, its amide or ester, or salts, and DNA encoding the same can be employed for obtaining antibodies and antisera, constructing the expression system of the protein of the present invention, for constructing the assay system for the GABA transporter activity and screen medicament candidate compounds using the expression system, for making drug design based on the steric structure of GABA transporters, as agents for producing probes or PCR primers in gene diagnosis, for preparing transgenic animals or as pharmaceuticals for the prevention/treatment of genetic disorders.

Abstract: A compound and method for using the compound to reduce injury associated with ischemia and reperfusion of mammalian organs such as the heart. The compound, either Deltorphin A and/or Dermorphin H, may be administered as part of a preconditioning strategy which reduces the extent of injury and improves organ function following cessation and restoration of blood flow. The compound may be used in preparation for planned ischemia or in a prophylactic manner in anticipation of further ischemic events.

Abstract: A procedure for the solid phase peptide synthesis (SPPS), following a linear or convergent strategy, wherein the peptides contain the sequence of general formula (I), wherein n, Y, X and A1 to An have the meanings indicated in the specification. Said procedure comprises: the use of amino acids with the N? group protected, protecting the side chains of those amino acids that have their side chain alkylated or acylated in the final product with labile protecting groups, protecting the side chains of at least one of the amino acids that has its chain free in the final product with hyperlabile products and using a polymeric support which provides labile peptide-resin bonds. Said procedure is valid for the synthesis of gosereline and busereline Y—A1—A2—A3— . . . A(n-1)—An—X.

Abstract: Disclosed is a lyophilized preparation of recombinant factor VIII used as a therapeutic preparation of hemophilia A. The lyophilized preparation of recombinant factor VIII is prepared by performing lyophilization using a mixture comprising 6 to 100 mM of L-arginine, 3.5 to 50 mM of L-isoleucine, and 10 to 100 mM of L-glutamic acid as a stabilizer for stabilizing the recombinant factor VIII which exhibits an unstable activity during lyophilization, rather than using human blood derived albumin.

Abstract: Methods of treating a mammal in shock or at risk for shock are provided. The methods involve administration of an adrenomedullin binding protein-1 to the mammal. Also provided are methods of preventing or treating a physiologic effect of shock in a mammal. These methods also involve administration of an adrenomedullin binding protein-1 to the mammal.

Abstract: Polypeptides that comprise an approximately 100-amino acid residue region of a centrosomal P4.1-associated protein (CPAP) that possess microtubule-destabilizing activity, polynucleotides encoding such polypeptides, compositions comprising the polypeptides and polynucleotides, and methods of use thereof, are disclosed. The invention is useful for destabilizing microtubules in eukaryotic cells, including but not limited to cancer cells.

Abstract: The present invention provides methods of preventing organ destruction and shut-down due to shock in a patient suffering from sepsis or at risk for sepsis, comprising administering adrenomedullin and adrenomedullin binding protein-1 to the patient. Also provided are compositions containing adrenomedullin and adrenomedullin binding protein-1 or precursors, in a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a protein having an activity of giving a lysozyme insensitivity to a lysozyme-sensitive microorganism belonging to Corynebacterium glutamicum; DNA which codes for the protein; a recombinant vector containing the DNA; a transformant obtained by introducing the recombinant vector into a host cell; a bacterium having a lysozyme sensitivity in which the activity of the protein is inactivated; and a method for producing an amino acid using the bacterium.

Abstract: The combination of recombinant factor VIIa and fibrinogen is effective in treatment for bleeding where direct pressure, tourniquets, indirect pressure, surgical ligation, bandaging, and transfusion of blood or plasma products are typically used. The combination of factor VIIa and fibrinogen is administered intravenously, either sequentially or simultaneously. The compositions may be safely circulated in the blood vessels to sites of injury. This is effective for single or multiple external or internal wounds.